Camelid TB Serology Quarterly Report: 1st April to 30th June 2024
Source: environment.data.gov.uk (2024-10-03)

Camelid TB Serology Quarterly Report. Camelid TB Serology Quarterly Report.

Camelid TB Serology
Quarterly Report
Number: 37
Report Period 1st April to 30th June 2024
Issued 12/Jul/2024

Submission Reason
Explanation
APHA /DEFRA
At Government expense
Parallel Test:
PAR-TB
TB breakdown herd with confirmed M. bovis infection (including Wales where Officially
TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)
PAR-SUS
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions
PAR-TRC
Forward  tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in
Wales only co-located on the same premises with infected cattle, sheep, deer, goats
& pigs)
PAR-COL-W
Wales only - camelids under restriction due to sharing a holding (colocation) with an
OTFW cattle herd or with other non-bovine animals affected by a culture-confirmed
incident
Serial Test:
SER-SUS (replaces PA
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions. If infection is confirmed the initial High Specificity (serial) test results can
be reinterpreted at High Sensitivity on request from the APHA case vet.
SER-CONT
Herd not under restriction but contiguous to a TB-infected herd
SER-COL
Herd not under restriction but co-located with an infected herd of cattle, deer, goats
etc. (Eng & Scot only)
SER-EPI
Herd not under restriction but TB tested due to an epidemiological link with a known
infected herd (e.g. back-tracing)
SER-CHK
Inconclusive Reactor check test – e.g. where private Enferplex test has produced a
2-spot-positive result on 2 consecutive occasions
Commercial/Private
At Owner expense
SER-MVT
Pre- or post-movement test
SER-EXP 
Pre-export test
SER-DIAG
Diagnostic to exclude TB from a differential diagnoses in a herd not restricted (TB
strongly suspected)
SER-RHT
Monitoring - voluntary routine testing (herd nor restricted)
Quarterly Camelid Serology Report
Test Criteria
The camelid TB serology (antibody) test generally comprises two separate antibody tests in a test package that can be
applied flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test
interpretation respectively. The sensitivity and specificity values of combined antibody testing for camelids were described
under AHVLA Project FT1477 (see Rhodes et al., 2012) and re-assessed in May 2018 to show the following test
performance;
IDEXX /DPP VetTB
ENFER 2-SPOT/DPP VetTB
IDEXX/ENFER 2-SPOT
% Se
74
71
75
95% C.I.
65.4-82.6
62.1-79.9
66.5-83.5
% Sp
96
96.7
97.3
95% C.I.
93.8-98.2
95.8-99.4
95.4-99.1
Fishers Exact [2-sided] test showed no significant difference in sensitivity or specificity between any of these three test options.
Table 2 – High Specificity / Serial test options:
Table 1 – High Sensitivity / Parallel test options:
Fishers Exact [2-sided] test showed no significant difference in test sensitivity or specificity between these two test options.
ENFER 4-SPOT
IDEXX/DPP VetTB
% Se
60
56
95% C.I.
50.4-69.9
46.3-65.7
% Sp
99.66
100
95% C.I.
98.9-100
Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko,
K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and
antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.

Quarterly Camelid Serology Report
12 Jul 2024
Table 1a
Country
No.
Samples
Tested
England
198
Wales
16
Scotland
1
Total for Q2
215
Number of Samples tested and Submission Reason  2024 Q2 (April - June)
Table 1b
Submission
Reason
No. Samples
Tested
Parallel
PAR-COL-W
12
PAR-TB
4
Parallel
Sum:
16
Serial
SER-COL
4
SER-CONT
113
SER-EPI
78
Serial
Sum:
195
Commercial/Private Testing
SER-MVT
4
Commercial/Private Testing
Sum:
4
Total for Q2
Sum:
215

Quarterly Camelid Serology Report
12 Jul 2024
Table 2a
Country
No.
Samples
Tested
England
345
Wales
65
Scotland
1
Total for Q2
411
Number of Samples tested and Submission Reason 2024 up to end of Q2 (January - June)
Table 2b
APHA/DEFRA
Submission
Reason
No.
Samples
Tested
Parallel
PAR-COL-W
12
PAR-TB
22
PAR-TRC
3
Parallel
Sum:
37
Serial
SER-CHK
1
SER-COL
41
SER-CONT
246
SER-EPI
78
Serial
Sum:
366
Commercial/Private Testing
SER-DIAG
1
SER-MVT
7
Commercial/Private Testing
Sum:
8
Total for 2024 up to end
of Q2
411

Quarterly Camelid Serology Report
12 Jul 2024
Table 3a
Submissions Received and Test Positivity in 2024 Q2
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Serial
SER-COL
2
4
0
0
SER-CONT
16
113
1
0.9%
SER-EPI
9
78
0
0
Serial
27
195
1
0.5%
Commercial/Private Testing
SER-MVT
1
3
0
0
Commercial/Private Testing
1
3
0
0
England Total
28
198
1
0.5%
Wales
Parallel
PAR-COL-W
2
12
1
8.3%
PAR-TB
1
4
0
0
Parallel
3
16
1
6.3%
Wales Total
3
16
1
6.3%
Scotland
Commercial/Private Testing
SER-MVT
1
1
0
0
Commercial/Private Testing
1
1
0
0
Scotland Total
1
1
0
0
Totals for Q2
32
215
2
0.9 %
Test Positivity in 2024 Q2 (April - June)

Quarterly Camelid Serology Report
12 Jul 2024
Table 3b
Submissions Received and Test Positivity in 2024 up to the end of Q2
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-TB
3
12
3
25.0%
PAR-TRC
1
3
0
0
Parallel
4
15
3
20.0%
Serial
SER-CHK
1
1
0
0
SER-COL
4
9
0
0
SER-CONT
41
235
3
1.3%
SER-EPI
9
78
0
0
Serial
55
323
3
0.9%
Commercial/Private Testing
SER-DIAG
1
1
0
0
SER-MVT
3
6
0
0
Commercial/Private Testing
4
7
0
0
England Total
63
345
6
1.7%
Wales
Parallel
PAR-COL-W
2
12
1
8.3%
PAR-TB
2
10
0
0
Parallel
4
22
1
4.5%
Serial
SER-COL
2
32
0
0
SER-CONT
4
11
0
0
Serial
6
43
0
0
Wales Total
10
65
1
1.5%
Scotland
Commercial/Private Testing
SER-MVT
1
1
0
0
Commercial/Private Testing
1
1
0
0
Scotland Total
1
1
0
0
Totals up to
end Q2
74
411
7
1.7 %
Test Positivity in 2024 up to end of Q2 (January - June)

Quarterly Camelid Serology Report
12 Jul 2024
Submissions Received in 2024 up to end of Q2
Analysis
Analysis Description
Q1
No.
samples
tested
Q2
No.
samples
tested
Totals up to end Q2
TC0503
Camelid TB Enferplex - 2
Spot
15
15
TC0603
Camelid TB Enferplex - 4
Spot
102
139
241
TC0611
Chembio DPP VetTB lateral
flow rapid antibody test
79
76
155
TC0867
Camelid TB Antibody
ELISA
94
76
170
Table 4: Number of samples Tested by Test Code